Use of lactobacillus salivarius

Abstract

Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.

1 - 50 . (canceled)  
     
     
         51 . (canceled)  
     
     
         52 . A method of treating or preventing inflammation or an inflammatory disease in a subject which comprises administering to the subject a preparation comprising a  Lactobacillus salivarius  strain of  Lactobacillus salivarius  wherein the  Lactobacillus salivarius  strain is of human origin.  
     
     
         53 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  effects changes in an immunological marker when introduced into a system comprising cells which interact with the immune system and cells of the immune system.  
     
     
         54 . The method as claimed in  claim 53  wherein the cells which interact with the immune system are epithelial cells.  
     
     
         55 . The method as claimed in  claim 53  wherein the immunological marker is a cytokine.  
     
     
         56 . The method as claimed in  claim 55  wherein the cytokine is TNFα.  
     
     
         57 . The method as claimed in  claim 53  wherein the cells which interact with the immune system and the immune system cells are of matched origin.  
     
     
         58 . The method as claimed in  claim 53  wherein the cells which interact with the immune system are of an origin selected from gastrointestinal, respiratory and genitourinary.  
     
     
         59 . The method as claimed in  claim 53  wherein the cells of the immune system are of an origin selected from gastrointestinal, respiratory and genitourinary.  
     
     
         60 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  strain is  Lactobacillus salivarius  subspecies  salivarius.    
     
     
         61 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  is isolated from resected and washed human gastrointestinal tract.  
     
     
         62 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  inhibits a broad range of Gram positive and Gram negative micro-organisms.  
     
     
         63 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  secretes a product having anti-microbial activity into a cell-free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E.  
     
     
         64 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  strain is strain UCC 118 [NCIMB40829].  
     
     
         65 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  is a genetically modified mutant of strain UCC 118 [NCIMB40829].  
     
     
         66 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  is a naturally occurring variant of strain UCC 118 [NCIMB40829].  
     
     
         67 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  is in the form of viable cells.  
     
     
         68 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  is in the form of non-viable cells.  
     
     
         69 . The method as claimed in  claim 52  wherein the undesirable inflammatory activity is undesirable gastrointestinal inflammatory activity.  
     
     
         70 . The method as claimed in  claim 69  wherein the gastrointestinal inflammatory activity is inflammatory bowel disease.  
     
     
         71 . The method as claimed in  claim 69  wherein the gastrointestinal inflammatory activity is Crohns disease.  
     
     
         72 . The method as claimed in  claim 69  wherein the gastrointestinal activity is ulcerative colitis.  
     
     
         73 . The method as claimed in  claim 69  wherein the gastrointestinal inflammatory activity is irritable bowel syndrome.  
     
     
         74 . The method as claimed in  claim 69  wherein the gastrointestinal inflammatory activity is pouchitis.  
     
     
         75 . The method as claimed in  claim 69  wherein the gastrointestinal inflammatory activity is post infection colitis.  
     
     
         76 . The method as claimed in  claim 69  wherein the inflammatory activity is due to gastrointestinal cancer.  
     
     
         77 . The method as claimed in  claim 52  wherein the inflammatory activity is systemic inflammatory disease.  
     
     
         78 . The method as claimed in  claim 77  wherein the systemic inflammatory disease is rheumatoid arthritis.  
     
     
         79 . The method as claimed in  claim 52  wherein the undesirable inflammatory activity is due to an autoimmune disorder.  
     
     
         80 . The method as claimed in  claim 52  wherein the undesirable inflammatory activity is due to cancer.  
     
     
         81 . The method as claimed in  claim 52  wherein the  Lactobacillus salivarius  is contained in a formulation.  
     
     
         82 . The method as claimed in  claim 81  wherein the formulation includes another probiotic material.  
     
     
         83 . The method as claimed in  claim 81  wherein the formulation includes a prebiotic material.  
     
     
         84 . The method as claimed in  claim 81  wherein the formulation includes an ingestable carrier.  
     
     
         85 . The method as claimed in  claim 84  wherein the ingestable carrier is a pharmaceutically acceptable carrier.  
     
     
         86 . The method as claimed in  claim 84  wherein the ingestable carrier is selected from one or more of a protein, a peptide, a lipid, a carbohydrate, a vitamin, a mineral, and a trace element.  
     
     
         87 . The method as claimed in  claim 84  wherein the ingestable carrier is a food product.  
     
     
         88 . The method as claimed in  claim 81  wherein the  Lactobacillus salivarius  is present at more than 10 6  cfu per gram of the formulation.  
     
     
         89 . The method as claimed in  claim 81  wherein the formulation includes an ingredient selected from one or more of an adjuvant, a bacterial component, a drug entity, and a biological compound.  
     
     
         90 . A method of treating or preventing a diarrhoeal disease in a subject comprising administering to the subject a preparation comprising a  Lactobacillus salivarius  strain wherein the  Lactobacillus salivarius  strain is of human origin.  
     
     
         91 . A method of treating or preventing inflammation or an inflammatory disease in a subject comprising administering to the subject a preparation comprising  Lactobacillus salivarius  strain UCC 118 [NCIMB40829].  
     
     
         92 . A method of treating or preventing a diarrhoeal disease in a subject comprising administering to the subject a preparation comprising  Lactobacillus salivarius  strain UCC 118 [NCIMB40829].